Literature DB >> 15597260

[A clinical and epidemiological description of a series of patients diagnosed as suffering from progressive supranuclear palsy].

E Alvarez-González1, C Maragoto-Rizo, M Arteche-Prior, S Pérez-Parra, M Carballo, L Alvarez-González.   

Abstract

INTRODUCTION: Progressive supranuclear palsy is a disease that normally presents only sporadically in adults and courses in a progressive, chronic manner. It is characterised by the presence of supranuclear ophthalmoplegia, postural instability, a Parkinsonian syndrome, pseudobulbar affect, cervical dystonia and cognitive impairment. PATIENTS AND METHODS: We conducted a descriptive study of clinical and epidemiological features in a series of 18 patients who satisfied the mandatory NINDS-SPSP clinical eligibility criteria for the likely diagnosis of progressive supranuclear palsy, using the scale developed by Golbe et al. RESULTS AND
CONCLUSIONS: The mean age of onset of the disease was 58.6 +/- 8.2 years, 55.5% of the patients were males, the average history of the disease at the time of diagnosis was 4.39 +/- 2.3 years, and there was a diagnostic subregister in the first 4 years of the disease. Gait disorders, falls and slowness were the most frequently observed presenting forms of the disease. During their first four years with the disease, 75% of the patients were totally independent when it came to carrying out activities of daily living, whereas after the fourth year there was a predominance of the need for aid and absolute dependence. Dysphagia was more frequent in the later stages of the disease. Ocular motility disorders and impaired cognitive functioning were obvious in the initial stages of the disease, and there was a strong correlation between the length of time the disease had been coursing and the severity of the ocular and cognitive disorders.

Entities:  

Mesh:

Year:  2004        PMID: 15597260

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  2 in total

1.  Functional impairment in progressive supranuclear palsy.

Authors:  Kevin Duff; Adam Gerstenecker; Irene Litvan
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

2.  Clinical features and disability milestones in multiple system atrophy and progressive supranuclear palsy.

Authors:  Sang-Wook Lee; Seong-Beom Koh
Journal:  J Mov Disord       Date:  2012-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.